In Regard to Shortall et al.

Disclosures: M.R.S. discloses research grants and drug costs or biomarker testing costs (all to the institution and all active in the past 36 months, but on research outside this research) from Astellas, Clovis Oncology, Janssen, Pfizer, Novartis, and Sanofi-Aventis; speaker fees at clinical trial statistics training meeting for clinicians (no discussion of particular drugs) from Lilly Oncology and Janssen; and independent membership of many independent data monitoring committees, but all for academic sponsors and none paid.